BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced that the Company’s proprietary bioartificial liver device has successfully demonstrated key ...

Boston, MA - HepaLife Technologies, Inc. recently announced that new tests of its bioartificial liver device demonstrate the Company's bioreactor system and patented PICM-19 cells inside the device ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--May 22, 2006--HepaLife Technologies, Inc. (OTCBB:HPLF - News; FWB:HL1), today announces that the National Institutes of Health (NIH) has launched a $71 ...

Boston, MA - HepaLife Technologies, Inc. is pleased to announce details of a series of significant achievements in the development of the first-of-its-kind bioartificial liver device, allowing the ...

BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625), developer of the first-of-its-kind artificial liver device, today announced the appointment of its Vice ...

NEW YORK--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (“HepaLife”), an advanced biomedical products company focused on the development and manufacturing of proprietary drug ...

NEW YORK, Nov. 1, 2010 (GLOBE NEWSWIRE) -- HepaLife Technologies, Inc. (OTCBB:HPLF) (Frankfurt:HL1) ("HepaLife"), an advanced biomedical products company focused on the development and manufacturing ...

New Subsidiary to Focus on Development, Manufacturing and Marketing of Proprietary Transdermal Drug Delivery Products in High-Growth Sectors NEW YORK, New York - November 1, 2010 - HepaLife ...

Medical device company HepaLife Technologies Inc., has purchased certain assets of Waltham-based Arbios Systems Inc., picking up that company’s HepatAssist liver support technology, along with ...

HepaLife Technologies Inc. (OTC:HPLF) has acquired the maker of hydrogels used for transdermal drug delivery in an all-stock deal valued at about $16 million. In addition to the May 11 all-stock deal ...

HepaLife Technologies, based in New York, is launching a new subsidiary that will take advantage of the transdermal drug delivery technology it acquired when it bought AquaMed Technologies in May.

HepaLife Technologies, Inc. (OTCBB:HPLF): -- Worldwide License Agreement Supported by 5 Issued Patents for the Development of New Flu Vaccines to Protect against the Spread of Influenza Viruses among ...